close
QUICK
MENU
Partners Media Releases Contact Us
팝업 로고
Introducing CUBEBIO’s cancer self-diagnostic device

CUBEBIO’s cancer self-diagnostic device is capable of detecting 8 major cancer types (breast cancer, colorectal cancer, stomach cancer, liver cancer, lung cancer, pancreatic cancer, prostate cancer, and bladder cancer) at an early stage by using urine as a specimen.

As you start the device, you will be able to see ‘Test,’ ‘Instruction,’ ‘Administrator,’ ‘Illness History,’ ‘Summary,’ and ‘Setting’ on a screen. First, you put urine on a sensor. Next, you place it on a tray and insert it into an analyzer. Then, you press the ‘Test’ button with a light touch.

In about 15 minutes, you can do whatever you want, whether it be drinking a cup of coffee, taking a shower, or working, in a variety of settings, including home, hospital, pharmacy, coffee shop, office, convenience store, and bank. Finally, you check the diagnostic result on the screen, save it in your medical history, and monitor your health status on a frequent basis.

※ This video will be promoted worldwide in the first half of this year.

Close for 1day Close
팝업 로고
pamphlet1 pamphlet2 Introducing CUBEBIO and the company’s cancer self-diagnostic device

This brochure consists of 7 subjects:

1) Introducing CUBEBIO
2) Introducing CUBEBIO’s partners
3) Introducing ‘Cancer Early Detection and Self-Diagnosis’ program jointly developed by CUBEBIO and the Union for International Cancer Control
4) Introducing CUBEBIO’s cancer self-diagnostic device
5) Explaining how to use CUBEBIO’s cancer self-diagnostic device
6) Elaborating on CUBEBIO’s vision to create a new culture with its cancer self-diagnostic device
7) Showing a picture of the main parts of CUBEBIO’s cancer self-diagnostic device (an analyzer and a sensor)

Close for 1day Close
팝업 로고
nice popup CUBEBIO receives 'TI-3' rating for investment-type technology assessment, TCB (Technology Credit Bureau)

On February 28, 2020, CUBEBIO was recognized for its excellence in technology by acquiring the 'TI-3' rating of investment-type technology evaluation from NICE Information Service Co., Ltd. TCB (Technology Credit Bureau) is an evaluation of the economic value of technologies that can be generated through the technology commercialization, such as value, grade, or score. Based on the technology, NICE Information Service comprehensively analyzes and evaluates the technical ability, business feasibility, marketability, and management capabilities of the company. Technical evaluation for investment divides into 10 different grades from TI-1 to TI-10. (TI-1 being the best, TI-10 being the worst). TI-3, the third highest grade acquired by CUBEBIO, are awarded to companies with excellent technical skills that can be considered for the listing with a technical exception in Korea.

Close for 1day Close

visual

mainVisual mainVisual2

Innovation in Cancer Diagnosis

We will become the world’s top in vitro diagnostic company by contributing to the
promotion of people’s health and happiness through early cancer detection.

About CUBEBIO

About
CUBEBIO

As a biomedical company specializing in cancer diagnosis, CUBEBIO is committed to global health improvements through early screening and detection of cancer. We are also a research-oriented company with competitive networking and marketing skills by forming mutually beneficial partnerships.
Business Contact Us

Research&Development

Research & Development

R&D

Unlike healthy cells, amino acid, glucose, nucleic acid precursor, protein,
and other elements are metabolized in larger quantities and excreted in urine at different concentrations in the development of cancer.
We can check the existence or non-existence of cancer by measuring these concentrations.
Technology Products Patents

Partners

Partners

Introducing CUBEBIO’s partner,
Union for International Cancer Control (UICC) View More

Latest News

Latest News

2020-0525

[2020.05.25]CUBEBIO, in vitro diagnostic company, awarded the Biotechnology Grand Prize


 최은종 큐브바이오 대표(사진 오른쪽)가 22일 오후 서울 중구 한국프레스센터에서 열린 머니투데이 주최의 '2020 제6회 대한민국 우수기업대상' 시상식에서 '바이오대상'을 수상하고 정희경 머니투데이 전무와 기념 촬영 중이다.체외진단 전문기업 큐브바이오는 31개의 암 진단 관련 특허를 보유한 업체다. 다수 특허를 기반으로 8개 주요 암의 유무 및 암종을 확인할 수 있는 진단기기를 개발했다. 업체 측은 "러시아 국립방사선의료연구센터에서 위임받은 현지 업체와 5년간 약 3조원 규모의 공급 계약을 체결했다"면서 "올 하반기 수출을 위해 현재 대량 생산 공장을 구축 중"이라고 말했다. 큐브바이오는 국제암통제연합(UICC)의 최고 등급 파트너 '패트론파트너'로 등록된 기업이기도 하다. 기사출처:  머니투데이: https://news.mt.co.kr/mtview.php?no=2020052117380298747관련기사:  머니투데이: https://news.mt.co.kr/mtview.php?no=2020051918131888414
2020-0319

[2020.03.19]CUBEBIO Obtains 'Export Permit' for Urine Diagnosis Medical Devices - 1100 square meters of mass production facility is under construction.


큐브바이오, 소변진단 의료기기 `수출허가` 획득 -1100㎡ 규모 생산시설 설비 공사 진행 중  체외진단전문 기업 큐브바이오가 19일(오늘) 한국의료기기안전정보원으로부터 소변진단 의료기기제품에 대해 수출허가를 획득했다고 밝혔다. 해당 허가는 ‘의료기기 허가.신고.심사 등에 관한 규정(식약처 고시)’에 따라 이루어졌다. 큐브바이오는 해당 제품의 생산을 위해 3개 회사와 계약을 체결했으며, 3~4월 중 설비 공사 완료 및 테스트 생산을 진행했다. 오는 5~6월 중에는 수출 물량을 생산하기 위해 현재 인천시 부평에 위치한 1100㎡ 규모의 첨단 제조공장에서 클린룸 시설 및 생산설비 공사를 진행할 예정이다.큐브바이오는 소변을 검체로 사용하는 퓨린대사체 분석 키트와 가정, 병원, 약국 등에서 의료인의 도움 없이 편리하게 8종 암의 유무 판단과 암 종까지 확인할 수 있는 멀티 추적 시스템을 개발한 회사다. 화이자나 로슈 등 유명 글로벌 제약사와 함께 세계에서 가장 크고 오래된 암 협회인 국제암통제연합(UICC)의 가장 상위 등급인 패트론 파트너로도 알려져 있다.   기사출처:  매일경제: https://www.mk.co.kr/news/society/view/2020/03/286823/ 관련기사:   한국경제: https://www.hankyung.com/economy/article/202003194581a  서울경제: https://www.sedaily.com/NewsView/1Z09E3YMMV  동아일보: http://www.donga.com/news/article/all/20200319/100240119/2
2020-0309

[2020.02.28]CUBEBIO receives 'TI-3' rating for investment-type technology assessment, TCB (Technology Credit Bureau), recognized as 'excellent technology'


체외진단 전문기업 큐브바이오는 기술평가 업체인 나이스평가정보㈜로부터 투자형 모형으로 기술 평가를 받은 결과 기술력이 우수한 기업에 해당하는 TI-3 등급을 받았다고 28일 밝혔다.나이스평가정보에 따르면 기술신용평가(TCB·Tech Credit Bureau)는 기술 사업화를 통해 발생할 수 있는 기술의 경제적 가치를 가액·등급 또는 점수 등으로 평가하는 것을 가리킨다. 기술력을 중심으로 기업의 기술성, 권리성, 시장성, 사업성을 종합적으로 분석·평가한다.  기사출처:  동아일보: http://www.donga.com/news/article/all/20200228/99920842/2 관련기사:  매일경제: https://www.mk.co.kr/news/society/view/2020/02/207694/  한국경제: https://www.hankyung.com/economy/article/202002282666a  중앙일보: https://news.joins.com/article/23718062  메디컬투데이: http://www.mdtoday.co.kr/mdtoday/index.html?no=379174
View More